Clinical Trials Logo
  1. Home
  2. Cytokine Release Syndrome
  3. NCT04048434
  4. Details
NCT04048434 Clinical Trial

Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)

Cytokine Release Syndrome Clinical Trial

— CYTORELEASE  

Official title:
Effectivity of Extracorporeal Cytokine Adsorption (Cytosorb) as Additive Treatment of CAR-T Cell Associated Cytokine Release (CRS) Syndrome and Encephalopathy Syndrome (CRES)

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04048434
Other study ID # CRS01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 2021
Est. completion date September 2024

Study information
Verified date March 2021
Source Hannover Medical School
Contact Sascha David, MD
Phone +495115329357
Email david.sascha@mh-hannover.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with severe CAR-T cell associated cytokine release syndrome (CRS) (defined as vasopressor dependent) will be treated with standard of care (SOC) + cytokine adsorption (6hourly for 24 hrs). Primary endpoint is the change in plasma IL-6 between 0 and 24 hrs.

Recruitment information / eligibility
Status Recruiting
Enrollment 34
Est. completion date September 2024
Est. primary completion date September 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - severe CRS (> 3) and / or severe CRES (>3) AND - CRS/CRES onset < 6 hrs Exclusion Criteria: - Heparine allergy - contraindication for anticoagulation

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• Cytosorb
extracorporeal cytokine adsorption

Locations
Country Name City State
Germany Hannover Medical School Hannover
Switzerland Universitätsspital Zürich (USZ) Zürich

Sponsors (2)
Lead Sponsor Collaborator
Hannover Medical School CytoSorbents, Inc

Countries where clinical trial is conducted

Germany,  Switzerland, 

Outcome
Type Measure Description Time frame Safety issue
Primary IL-6 change 24 hours
See also
  Status Clinical Trial Phase
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Terminated NCT04540120 - Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome Phase 2
Terminated NCT03557749 - Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
Active, not recruiting NCT04150913 - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Phase 2
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04975555 - Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Phase 2
Terminated NCT04403685 - Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers Phase 3
Completed NCT04366908 - Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome Phase 2
Completed NCT05349669 - Jafron Haemoadsorption During Cardiopulmonary Bypass Phase 2
Completed NCT04720378 - Safety and Tolerability Study of IV ST266 in COVID-19 Subjects Phase 1
Terminated NCT04415073 - A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 Phase 2
Completed NCT03533101 - Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation Phase 1/Phase 2
Completed NCT04403061 - Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Completed NCT04475588 - Efficacy and Safety of Itolizumab in COVID-19 Complications Phase 2
Terminated NCT04377503 - Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 Phase 2
Recruiting NCT04781803 - Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome Phase 2
Completed NCT01353157 - Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery N/A
Completed NCT04048525 - Cytokine Removal With CVVHD Compared to CVVH N/A
Recruiting NCT04486521 - Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19